LENSAR (LNSR) Hisse Özeti
Ticari aşamada bir tıbbi cihaz şirketi olan LENSAR, Inc. Birleşik Sistem, Avrupa, Asya, Güney Kore ve uluslararası alanda katarakt tedavisi ve önceden var olan veya cerrahi olarak indüklenen korneal astigmatizmanın yönetimi için lazer sistemleri tasarlamaya, geliştirmeye ve pazarlamaya odaklanmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
LNSR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LENSAR, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$6.20 |
| 52 Haftanın En Yüksek Seviyesi | US$13.47 |
| 52 Haftanın En Düşük Seviyesi | US$5.06 |
| Beta | 0.87 |
| 1 Aylık Değişim | 11.91% |
| 3 Aylık Değişim | -5.78% |
| 1 Yıllık Değişim | -49.55% |
| 3 Yıllık Değişim | 54.42% |
| 5 Yıllık Değişim | -21.52% |
| Halka arzdan bu yana değişim | -31.11% |
Son Haberler & Güncellemeler
LNSR: Post Deal Selloff Will Set Up Margin Led Repricing Potential
Analysts have lifted their price target on LENSAR to $10, citing stronger profit margin expectations, a lower assumed discount rate, and a reduced future P/E, even as projected revenue growth is now more conservative. Analyst Commentary Bullish Takeaways Bullish analysts highlight the $10 price target as reflecting confidence that LENSAR's expected profit margins can support a higher valuation multiple than previously assumed.LNSR: Buy Thesis Will Rebuild Around Post Deal Selloff And Adoption Reacceleration
Analysts have nudged their price target on LENSAR stock to $8.50, with recent upgrades to Buy and renewed confidence around the ALLY System adoption story cited as key reasons for the updated view. Analyst Commentary Recent research has focused on how the ALLY System adoption story and the fallout from the halted Alcon acquisition are shaping expectations for LENSAR’s execution and valuation.LNSR: Buy Thesis Rebuilds Around Post Deal Selloff And Adoption Reacceleration
Analysts have raised their price targets on LENSAR shares to $10, citing renewed optimism around ALLY System adoption and viewing the post acquisition setback selloff as a second chance for investors. Analyst Commentary Bullish Takeaways Bullish analysts point to a $10 price target as a simple yardstick for how they frame upside potential if ALLY System adoption trends seen before the Alcon deal announcement can be re established.Recent updates
LNSR: Post Deal Selloff Will Set Up Margin Led Repricing Potential
Analysts have lifted their price target on LENSAR to $10, citing stronger profit margin expectations, a lower assumed discount rate, and a reduced future P/E, even as projected revenue growth is now more conservative. Analyst Commentary Bullish Takeaways Bullish analysts highlight the $10 price target as reflecting confidence that LENSAR's expected profit margins can support a higher valuation multiple than previously assumed.LNSR: Buy Thesis Will Rebuild Around Post Deal Selloff And Adoption Reacceleration
Analysts have nudged their price target on LENSAR stock to $8.50, with recent upgrades to Buy and renewed confidence around the ALLY System adoption story cited as key reasons for the updated view. Analyst Commentary Recent research has focused on how the ALLY System adoption story and the fallout from the halted Alcon acquisition are shaping expectations for LENSAR’s execution and valuation.LNSR: Buy Thesis Rebuilds Around Post Deal Selloff And Adoption Reacceleration
Analysts have raised their price targets on LENSAR shares to $10, citing renewed optimism around ALLY System adoption and viewing the post acquisition setback selloff as a second chance for investors. Analyst Commentary Bullish Takeaways Bullish analysts point to a $10 price target as a simple yardstick for how they frame upside potential if ALLY System adoption trends seen before the Alcon deal announcement can be re established.
Cataract Procedure Bundling Will Pressure Margins Yet Recurring Revenue Should Support Gradual Recovery
Catalysts About LENSAR LENSAR develops and commercializes robotic femtosecond laser systems for cataract surgery, with a focus on its ALLY Robotic Laser Cataract System. What are the underlying business or industry changes driving this perspective?LNSR: Buy Rating Resets Around Post Deal Selloff And Execution Rebuild
Analysts have trimmed their price target for LENSAR to $8.50 from $12.50, reflecting updated views on revenue growth, profitability and a lower future P/E, while also pointing to recent upgrades that highlight renewed interest in the stock following the failed Alcon acquisition. Analyst Commentary Recent Street research has focused on the reset expectations for LENSAR following the failed Alcon transaction, as well as the potential runway for the company’s ALLY System.
Recurring Cataract Procedure Revenue And Machine Learning Will Transform This Undervalued Medical Device Story
Catalysts About LENSAR LENSAR develops and commercializes the ALLY Robotic Laser Cataract System for laser assisted cataract surgery. What are the underlying business or industry changes driving this perspective?LNSR: Buy Rating And Post Deal Reset Will Drive Future Reassessment
Analysts have trimmed their fair value estimate for LENSAR from $15.00 to $12.50, pointing to revised assumptions around discount rates, margins, and future P/E, alongside a BTIG upgrade to Buy that highlights past ALLY System adoption and the recent post acquisition selloff as a potential second chance for investors to reassess the story. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the cut in fair value to $12.50 still sits above the current $10 price target.Global System Placements Will Improve Operating Room Efficiency
Strong system placements and contract pipelines in international markets enhance potential for sustained revenue growth and competitive advantage.Even With A 28% Surge, Cautious Investors Are Not Rewarding LENSAR, Inc.'s (NASDAQ:LNSR) Performance Completely
Despite an already strong run, LENSAR, Inc. ( NASDAQ:LNSR ) shares have been powering on, with a gain of 28% in the...We're Hopeful That LENSAR (NASDAQ:LNSR) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, LENSAR...Market Might Still Lack Some Conviction On LENSAR, Inc. (NASDAQ:LNSR) Even After 28% Share Price Boost
LENSAR, Inc. ( NASDAQ:LNSR ) shareholders would be excited to see that the share price has had a great month, posting a...LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...LENSAR, Inc. (NASDAQ:LNSR) Doing What It Can To Lift Shares
With a price-to-sales (or "P/S") ratio of 1.3x LENSAR, Inc. ( NASDAQ:LNSR ) may be sending bullish signals at the...Here's Why Shareholders May Want To Be Cautious With Increasing LENSAR, Inc.'s (NASDAQ:LNSR) CEO Pay Packet
Key Insights LENSAR to hold its Annual General Meeting on 7th of May Salary of US$541.1k is part of CEO Nick Curtis's...LENSAR, Inc.'s (NASDAQ:LNSR) Shares Leap 33% Yet They're Still Not Telling The Full Story
LENSAR, Inc. ( NASDAQ:LNSR ) shares have continued their recent momentum with a 33% gain in the last month alone...Here's Why We're Watching LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Not Many Are Piling Into LENSAR, Inc. (NASDAQ:LNSR) Just Yet
LENSAR, Inc.'s ( NASDAQ:LNSR ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy right now...Here's Why We're A Bit Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Investors Continue Waiting On Sidelines For LENSAR, Inc. (NASDAQ:LNSR)
LENSAR, Inc.'s ( NASDAQ:LNSR ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy right now...This Broker Just Slashed Their LENSAR, Inc. (NASDAQ:LNSR) Earnings Forecasts
One thing we could say about the covering analyst on LENSAR, Inc. ( NASDAQ:LNSR ) - they aren't optimistic, having just...Will LENSAR (NASDAQ:LNSR) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Here's Why We're Not Too Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...LENSAR GAAP EPS of -$0.67, revenue of $8M
LENSAR press release (NASDAQ:LNSR): Q2 GAAP EPS of -$0.67. Revenue of $8M (+1.3% Y/Y). Adjusted EBITDA was -$4.3M for the quarter ended June 30, 2022 and -$2.3M for the quarter ended June 30, 2021. As of June 30, 2022, the company had cash and cash equivalents of $25.2M as compared to $31.6M at December 31, 2021. Based on its cash position and operational forecasts, the company believes it has sufficient cash to fund operations into 2024.LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Hissedar Getirileri
| LNSR | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | 9.0% | 0.03% | 2.2% |
| 1Y | -49.6% | -20.4% | 24.8% |
Getiri vs. Endüstri: LNSR geçen yıl % -20.4 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.
Getiri vs Piyasa: LNSR geçen yıl % 24.8 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| LNSR volatility | |
|---|---|
| LNSR Average Weekly Movement | 12.2% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: LNSR hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: LNSR 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2004 | 150 | Nick Curtis | www.lensar.com |
Ticari aşamada bir tıbbi cihaz şirketi olan LENSAR, Inc. katarakt tedavisi ve Birleşik Sistem, Avrupa, Asya, Güney Kore ve uluslararası alanda önceden var olan veya cerrahi olarak indüklenen korneal astigmatizmanın yönetimi için lazer sistemleri tasarlamaya, geliştirmeye ve pazarlamaya odaklanmaktadır. Şirket, görüntüleme, prosedür planlama, tasarım ve hassasiyet sağlayarak görsel sonuçlar elde etmede cerraha yardımcı olmak için tasarlanmış bir dizi tescilli teknolojiyi içeren LENSAR Lazer Sistemini sunmaktadır. Ayrıca, cerrahların tek bir ameliyathanede steril lazer destekli katarakt ameliyatı yapmalarına olanak sağlamak üzere tasarlanmış kompakt bir katarakt tedavi sistemi olan ALLY Robotik Katarakt Lazer Sistemi de sunmaktadır.
LENSAR, Inc. Temel Bilgiler Özeti
| LNSR temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$69.24m |
| Kazançlar(TTM) | US$29.40m |
| Gelir(TTM) | US$57.70m |
LNSR aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| LNSR gelir tablosu (TTM) | |
|---|---|
| Gelir | US$57.70m |
| Gelir Maliyeti | US$31.33m |
| Brüt Kâr | US$26.38m |
| Diğer Giderler | -US$3.02m |
| Kazançlar | US$29.40m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 2.43 |
| Brüt Marj | 45.71% |
| Net Kâr Marjı | 50.94% |
| Borç/Özkaynak Oranı | 0% |
LNSR uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/16 23:49 |
| Gün Sonu Hisse Fiyatı | 2026/06/16 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
LENSAR, Inc. 3 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Gorman | BTIG |
| Frank Takkinen | Lake Street Capital Markets, LLC |
| Richard Newitter | Leerink Partners LLC |